GENFIT to Present Update on Scientific and Corporate Progress at The Liver Meeting 2023

• GENFIT to lead 3 key events on ACLF during AASLD:
  • ACLF Day for Investors/Analysts on November 11, 2023
  • Patient Advocacy Council meeting on November 11, 2023
  • ACLF Investigator event on November 12, 2023
• Detailed interim data from the ELATIVE Phase 3 results evaluating elafibranor in PBC to be presented by GENFIT’s partner Ipsen, in a late breaking oral session on November 13, 2023
• GENFIT to present new data on its NASH¹ diagnostics technology

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), November 2 2023 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and severe liver diseases, today announced that it will present an update on its scientific and corporate progress at The Liver Meeting 2023 organized by the American Association for the Study of Liver Diseases (AASLD), which will take place in Boston, MA (USA) from November 10-14, 2023.

GENFIT to lead 3 key events on Acute on Chronic Liver Failure (ACLF) during AASLD

ACLF Day
GENFIT will host an Investor/Analyst event on Saturday, November 11, 2023 at 12.30pm ET in Boston with the participation of key stakeholders:

• Dr. Jennifer Lai (MD, MBA, FACP, Transplant hepatologist, University of California, San Francisco (UCSF), USA) will present the ACLF disease state, patient journey and unmet medical needs in ACLF
• Robert Stolper, Managing Principal and Pierre-Antoine Andre, Vice President from IQVIA will present the ACLF market opportunity

ACLF Investigator Event
GENFIT will host an ACLF Investigator event on Sunday, November 12, 2023 at 6.30pm ET at the Hilton Boston Back Bay, Westminster. Participants include study investigators, principal investigators and other healthcare professionals from the US, France, Germany and the UK.

Patient Advocacy Council Meeting
Two Patient Advocacy Council sessions will be held on Saturday November 11, 2023. Topics on the agenda include developing a robust patient engagement plan with a specific focus on ACLF, and further initiatives to facilitate patient access to innovative medicine through clinical trials and patient perspectives and insights. Participants in this event include Dr. Jennifer Lai (MD, MBA, FACP) and the Global Liver Institute.